anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
1438082 Softening hair PROCTER & GAMBLE CO 15 Feb 1974 [16 Feb 1973] 6932/74 Heading D1P An anhydrous composition, suitable on dilution with water for softening hair comprises 0.5 to 10% by weight of a persulphate MHSO5 where M is an alkali metal cation, 15 to 99% of an organic diluent selected from saturated hydrocarbons, saturated fluorohydrocarbons, saturated primary alcohols, saturated esters of alcohols and fatty acids where the alcohols contain 1 to 6 hydroxy groups, saturated polyoxyalkylene ethers of alcohols containing 1 to 6 hydroxy groups and mixtures thereof ("saturated" includes compounds containing an aryl group or groups) and 0.5 to 15% of an alkaline buffer which renders the pH of a 25% aqueous dispersion or solution of said composition within the range 7 to 11, preferably 8.5 to 9. The composition preferably includes a surfactant. Many soaps, anionic, semipolar nonionic, amphoteric and zwitterionic surfactants are specified including long chain tertiary amine oxides, long chain sulfoxides and long chain tertiary phosphine oxides. Compositions with little surfactant are used as a cream rinse, those with a substantial amount of detergent are used as a shampoo. Specified persulphates are the complex salt 2KHSO5-KHSO4-K2SO4 and the lithium, sodium, potassium rubidium and cesium salts. It may be as 1 to 840 micron particles. The preferred organic diluents are ethoxylated nonionic detergents in the form of a liquid or a soft wax. Specified detergents are formed by the reaction of ethylene oxide with the condensate of propylene oxide and propylene glycol, alkyl phenols, C8 to C22 aliphatic aclohols and the condensate of polypropylene oxide and ethylene diamine. Specified buffers are alkali metal and alkaline earth metal hydroxides, carbonates, bicarbonates phosphates, pyrophosphates tripolyphosphates and borates, a 2:1 mixture of sodium carbonate and sodium bicarbonate being preferred.
[GB1438082A]
Patients will not be prescribed hip precautions in the first 6 weeks after surgery. The hip precautions that will no longer be prescribed are: no hip flexion past 90º, no crossing the legs, and no twisting at the waist.
Trastuzumab emtansine (T-DM1), sacituzumab govitecan (SG), and trastuzumab deruxtecan (T-DXd) are three ADCs approved for the treatment of metastatic breast cancer (MBC). Since gastrointestinal toxicities have been commonly observed with these drugs in clinical trials, a pooled analysis evaluating gastrointestinal adverse events (AEs) in patients with MBC treated with ADCs in clinical trials was performed. PubMed, Embase, and the Cochrane Library were searched from inception until May 2023 for phase II and III clinical trials reporting frequency and severity of gastrointestinal AEs during treatment with ADCs. Data were retrieved for nausea, vomiting, diarrhea, constipation, and abdominal pain: overall and grade 3-4 toxicity rates according to NCI-CTCAE were collected and expressed as proportions. A pre-specified subgroup analysis according to the agent was also carried out. Fourteen studies, comprising 5608 patients, were included in the analysis. Gastrointestinal AEs were frequently registered with SG and T-DXd. A significantly higher frequency of nausea (65.6% with SG, 75% with T-DXd), vomiting (43.7% with SG, 45% with T-DXd), and diarrhea (59.7% with SG, 29% with T-DXd) was noticed with these ADCs compared to TDM-1. Furthermore, diarrhea was more frequently associated with SG (grade 3 in 7.5% of patients), while constipation and abdominal pain were less common. Gastrointestinal AEs, notably nausea and diarrhea, were frequently reported by MBC patients treated with SG and T-DXd in clinical trials. Since these ADCs are administered continuously until disease progression or occurrence of unbearable AEs, gastrointestinal toxicity may have a negative impact on patient quality of life. Therefore, appropriate management of gastrointestinal AEs is mandatory to ensure treatment efficacy and adherence.
The exercise group underwent 8-week, 3 times a week, 60-minute group exercise sessions, which were comprised of moderate-to-high intensity exercise and simultaneous cognitive tasks. The exercise group also performed moderate-intensity home aerobic exercises for at least 60 minutes per week.
For patients with symptomatic gallstones, surgery offers the advantage of immediate and permanent stone removal but carries a high risk in some patients. About 5% of cholecystectomized patients have residual symptoms or retained common duct stones. The spectrum of surgical risk varies as a function of age and the presence of disease other than cholelithiasis.

Mortality Rates for Cholecystectomy in the U.S. (National Halothane Study, JAMA 1966; 197:775-8) 27,600 Cholecystectomies (Smoothed Rates) Deaths/1000 Operations*** 

Women in good health or who have only moderate systemic disease and are under 49 years of age have the lowest surgical mortality rate (0.054); men in all categories have a surgical mortality rate twice that of women. Common duct exploration quadruples the rates in all categories. The rates rise with each decade of life and increase tenfold or more in all categories with severe or extreme systemic disease.
Participants will receive a weekly SMS Text or instant message on a topic related to COVID-19 testing over 12 weeks. In addition, participants will receive as-needed messages on updates of COVID-19 testing related information. The messages will be responsive to the rapid evolving developments and changes related to COVID-19 testing guidelines. Some of the messages will include a link to allow participants to get to the entire message/information on the study website.
As a result of morphological and functional changes that occur with aging, complications such as decrease in muscle mass, flexibility and muscle strength, decrease in sleep quality, social isolation and chronic diseases develop and cause a decrease in independence in activities of daily living (ADL). Increasing physical activity in the elderly is effective in maintaining general health status and maintaining independence during activities of daily living (ADL). However, the level of the participation to physical activities is quite low in old age. It's known that group-based exercises and technology-supported exercise training with virtual reality games increase participation in physical activity and improve motor functions and ADL. But, there is no study examining the effect of technology-supported group exercises on ADLs in the elderly. Therefore, the aim of our study is to find out the effects of technology-supported group exercises on ADLs in the elderly over 65 years of age.

The forty-two participants will be recruited and divided into three equal groups randomly. The group 1(n=14) will perform group-based virtual reality training and group 2(n=14) will receive individual virtual reality training for 45-minutes, twice a week for eight weeks. The third group group 3(n=14) will determined as the control group and they will continue their routine daily activities. Primary outcome measure will be Barthel Index of Activities of Daily Living. Secondary outcome measures will be Physical Activity Scale for the Elderly (PASE), Timed Up and Go (TUG) test, Single Leg Stance Test (SLST), Six Minute Walk Test, Geriatric Depression Scale (GDS), Physical Activity Enjoyment Scale (Paces).
The present invention provides replicating [100K−] adenovirus vectors that have an impairment in 100K activity. In particular preferred embodiments, the impairment is the result of a deletion in the 100K coding region of the adenovirus vector genome. It is further preferred that the adenovirus produces the E1 gene products. In an alternate embodiment, the adenovirus produces the E1a gene products, but has an impairment in the E1b coding region, such that replication of the virus is limited to p53− cells. Also described are methods of making and administering the inventive adenovirus vectors to a cell or to a subject. Further provided is use of the inventive [100K−] Ad vectors as a helper virus for the production of vector stocks of adeno-associated virus.
In children, pulmonary fibrosis (PF) is an extremely unusual entity that can be observed in some types of interstitial lung disease (ILD). Defining whether ILD is accompanied by PF is important for targeted therapy. Algorithm for the diagnosis of PF in children is not clearly established. Besides, the clinical, radiological, and histological definitions commonly used to diagnose particularly the cases of idiopathic PF in adult patients, is not applicable to pediatric cases. However, a few studies conducted in children offer good exemplary diagnostic approach to fibrosing ILD. Thorax high resonance computed tomography and/or lung biopsy scanning can provide valuable information about PF. Another issue that has not been clearly established is when to start antifibrotic treatment in pediatric patients with PF. The objective of this current review is to provide a comprehensive overview of pediatric PF by drawing upon adult research, particularly focusing on the areas of uncertainty.
Before the procedure, written and verbal consent will be obtained from the newborn's guardian and brief information will be given about the massage to be performed on the newborn. Before applying massage to premature babies, their 24-hour sleep duration will be evaluated with an actigraphy device. Starting from the face with gentle touches, massage will be applied to the baby's forehead, around the eyes and cheeks with 2 fingers, without pressing too much. Then, the chest area will be massaged with circular movements from right to left, and then the upper and lower extremities will be massaged. Finally, the massage will be completed by turning the baby face down and applying gentle pressure to the back area. Massage applications will be performed for 15 minutes every morning and evening for two days. On the morning of the second day, an actigraphy device will be attached to the premature babies' ankles and their 24-hour sleep will be re-evaluated.
PCT No. PCT/JP98/01986 Sec. 371 Date Nov. 1, 1999 Sec. 102(e) Date Nov. 1, 1999 PCT Filed Apr. 30, 1998 PCT Pub. No. WO98/50368 PCT Pub. Date Nov. 12, 1998A benzimidazole derivative of the formula (I) or its salt: wherein A is a single bond or a C1-2 alkylene group (this alkylene group may optionally be substituted by a C1-4 alkyl group), R6 is a C1-4 alkyl group (this alkyl group may optionally be substituted by a phenyl group), B is a C2-3 alkylene group (this alkylene group may optionally be substituted by a C1-4 alkyl group), X is an oxygen atom, a sulfur atom or NR7 (wherein R7 is a nitro group, a cyano group or a C1-4 alkoxy group), each of R1 and R2 which are independent of each other, is a hydrogen atom, a halogen atom, a C1-4 alkyl group or a C1-4 alkoxy group, E is a C1-2 alkylene group (this alkylene group may optionally be substituted by a C1-4 alkyl group), R3 is a phenyl group (this phenyl group may optionally be substituted by a halogen atom, a C1-4 alkyl group or a C1-4 alkoxy group), a C1-4 alkoxy group or a benzyloxy group, each of R4 and R5 which are independent of each other, is a C1-4 alkyl group (this alkyl group may optionally be substituted by a phenyl group), D is a C1-2 alkylene group (this alkylene group may optionally be substituted by a C1-4 alkyl group), and Ar is a phenyl group.
On the surface of a cell there are different surface molecules, so called receptors. These receptors bind specific ligands, through which the cell becomes affected by its surroundings. Receptor molecules are also found on the surface of viruses and other pathogens. In contrast, such receptors are used for the attachment of the pathogen to a specific protein in the host and thereby for initiating the infection process. If membrane receptors of the cell are blocked, the cell will be prevented from being affected by a specific ligand, and if surface receptors of a pathogen are blocked, the pathogen will be prevented from being infectious. This invention relates to compounds, which will form very strong complexes with and thereby inhibit the biological function of for the compound specific surface structures (receptors) on cells, pathogenic microorganisms or viruses. The invention also relates to the design and preparation of such compounds for use as drugs or as tools for analytical or diagnostic purposes. The compounds comprise two or more identical protein domains interlinked by a peptide having such a length that each of the protein domains can interact simultaneously with its specific surface structure and thereby block the function of its structure. The protein domains might be human interleukin 2 (IL-2).
PROBLEM TO BE SOLVED: To easily obtain an aqueous gel containing highly percutaneously absorbable calcium and useful as e.g. a thickening agent, dispersant, emulsion stabilizer, by mixing an aqueous caustic alkali salt solution of a carboxyvinyl polymer with an aqueous sodium alginate solution followed by adding calcium hydroxide to the resultant mixture. SOLUTION: This transparent and homogeneous aqueous gel is easily obtained by mixing an aqueous caustic alkali salt solution of a carboxyvinyl polymer prepared by neutralizing 1 pt.wt. of the carboxyvinyl polymer with 0.3-0.5 pt.wt. of a caustic alkali with an aqueous solution of 1-2 pts.wt. of sodium alginate followed by adding calcium hydroxide at a virtually the same amount as that of the caustic alkali needed to neutralize the carboxyvinyl polymer to the resultant mixed aqueous solution.
The actual dosage is 0.24 mg/eye given 4 times a day for a maximum daily dosage of 0.96mg (60μL KDR2-2 eyedrops concentration of 4.0 mg/mL), which will continues for 6 days plus 1 administration of 0.24 mg/eye in the morning of Day 7. That cohort might be optional based on emerging data from this study.
Acute kidney injury (AKI) is a major worldwide health concern that currently lacks effective medical treatments. PSMP is a damage-induced chemotactic cytokine that acts as a ligand of CCR2 and has an unknown role in AKI. We have observed a significant increase in PSMP levels in the renal tissue, urine, and plasma of patients with AKI. PSMP deficiency improved kidney function and decreased tubular damage and inflammation in AKI mouse models induced by kidney ischemia-reperfusion injury, glycerol, and cisplatin. Single-cell RNA sequencing analysis revealed that Ly6Chi or F4/80lo infiltrated macrophages (IMs) were a major group of proinflammatory macrophages with strong CCR2 expression in AKI. We observed that PSMP deficiency decreased CCR2+Ly6Chi or F4/80lo IMs and inhibited M1 polarization in the AKI mouse model. Moreover, overexpressed human PSMP in the mouse kidney could reverse the attenuation of kidney injury in a CCR2-dependent manner, and this effect could be achieved without CCL2 involvement. Extracellular PSMP played a crucial role, and treatment with a PSMP-neutralizing antibody significantly reduced kidney injury in vivo. Therefore, PSMP might be a therapeutic target for AKI, and its antibody is a promising therapeutic drug for the treatment of AKI.
A sulphuric acid ester of oxytetracycline is prepared by reacting oxytetracycline or a salt thereof with a sulphur trioxide sulphonating agent in an anhydrous reaction-inert organic solvent at a temperature of from -50 DEG C. to 100 DEG C., the mole ratio of sulphur trioxide present in the reaction mixture to oxytetracycline being at least 1 : 1.  The sulphonating agent may be sulphur trioxide or a sulphur trioxide complex of N,N-dimethylaniline, dioxane, pyridine, N,N-dimethylformamide or of a tertiary base such as triethylamine or trimethylamine.  The ester has the formula <FORM:0896452/IV (b)/1> and can serve as intermediate for the preparation of a variety of substituted derivatives of tetracycline. It can, for example, be nitrosated in the D-ring or in the 4-position to give a nitroso derivative which can be converted to an amino derivative which can be converted to diazonium salts and various coupling products thereof.  The amino group can also be replaced by halogen, hydroxyl, nitro or arsonic acid by known methods.  The sulphuric acid ester can also be directly brominated, nitrated or sulphonated.ALSO:Pharmaceutical preparations comprise a pharmaceutical carrier and a sulphuric acid ester of oxytetracycline prepared by reacting oxytetracycline or a salt thereof with a sulphur trioxide sulphonating agent (see Group IV (b)) and having the formula <FORM:0896452/VI/1> The preparations may be in the form of capsules, tablets, aqueous or alcoholic solutions, ointments or salves.
Jaundiced patients with bilirubin value \>80 μmol/L. Received G17DT immediately prior to biliary stenting.
Microglia, which are the resident innate immune cells of the central nervous system (CNS), have emerged as critical for maintaining health by not only ensuring proper development, activity, and plasticity of neurones and glial cells but also maintaining and restoring homeostasis when faced with various challenges across the lifespan. This chapter is dedicated to the current understanding of microglia, including their beneficial versus detrimental roles, which are highly complex, rely on various microglial states, and intimately depend on their spatiotemporal context. Microglia are first contextualized within the perspective of finding therapeutic strategies to cure diseases in the twenty-first century-the overall functions of neuroglia with relation one to another and to neurones, and their shared CNS environment. A historical framework is provided, and the main principles of glial neuropathology are enunciated. The current view of microglial nomenclature is then covered, notably by discussing the rejected concepts of microglial activation, their polarisation into M1 and M2 phenotypes, and neuroinflammation. The transformation of the microglial population through the addition, migration, and elimination of individual members, as well as their dynamic metamorphosis between a wide variety of structural and functional states, based on the experienced physiological and pathological stimuli, is subsequently discussed. Lastly, the perspective of microglia as a cell type endowed with a health status determining their outcomes on adaptive CNS plasticity as well as disease pathology is proposed for twenty-first-century approaches to disease prevention and treatment.
During water-CO2 hybrid colonoscopy, the operator has access to both water and CO2. In the left colon, predominately water is used to navigate the sigmoid. Once the splenic flexure is reached, a combination of water and CO2 is used to reach the caecum. On withdrawal, CO2 is permitted.
Soft-tissue sarcomas (STS) that arise from the retroperitoneum are rare malignancies that are anatomical located deep within the abdominal area and thus pose challenges to surgical and radiotherapeutic management of the patient. As a result, the local control and overall survival for patients with retroperitoneal sarcomas (RPS) are worse than STS from the extremities. Current treatment strategy involves pre-operative radiotherapy followed by surgery. Use of intensity-modulated radiotherapy (IMRT) in RPS had allowed for more conformal treatments with the aim of sparing normal tissues from high doses of irradiation. Yet the accuracy and coverage of IMRT depend highly on target motion, and little is known about the motion of RPS during the course of radiotherapy. As well, RPS are commonly in close proximity to sensitive organs for which the long-term toxicity and effect on quality of life secondary to radiation is unknown. The current study seeks to evaluate the extent of tumor motion during radiotherapy and the impact of radiotherapy to patient toxicity and quality of life. At the conclusion of this study, our results will hopefully identify the optimum PTV, the importance of different normal tissues and their dose-volume constraints, the role of image guidance, and the potential for dose escalation in the treatment of RPS.
Systemic and topical ophthalmic steroids have long been associated with ocular effects, such as glaucoma or cataracts. Periocular steroid injections and steroids applied to periocular skin have also been reported to increase intraocular pressure (IOP) and raised IOP is the major risk factor for glaucoma. Approximately 18 to 36% of the general population are corticosteroid responders. This response is increased to 46 to 92% in patients with primary open-angle glaucoma (POAG).

Allergic rhinitis affects up to 30% of adults and 40% of children in the United States. Topical nasal steroids are the most effective treatment option.Nonallergic rhinitis is a common disease that affects approximately 17 million persons in the United States; approximately 22 million have a combination of allergic and nonallergic rhinitis.Topical nasal steroids have demonstrated efficacy in the treatment of nonallergic rhinitis and are considered first-line empiric therapy.With the perceived safety of nasal steroids, their use for the treatment of upper respiratory allergy has become more common.However, inhaled and nasal steroids might be absorbed systemically. Although the systemic absorption of inhaled and nasal steroids has been established, the clinically relevant ocular side effects are poorly defined. A large prospective study in 1995 by Samiy et al reported no statistically significant increase of IOP in 187 patients without glaucoma taking inhaled steroids for various pulmonary conditions. Similarly, a large case-control study in 1997 cases suggested that the presence of nasal steroid use in patients with newly diagnosed glaucoma or OHT versus nonglaucomatous patients was not statistically significant (odds ratio, 1.02; 95% CI, 0.59-1.77). However, the number of patients taking continuous high-dose nasal steroids was too small for statistical analysis. In 1998, a small prospective study of 26 non-glaucomatous patients revealed no evidence of OHT or cataracts after prolonged use of nasal steroids after endoscopic sinus surgery (mean follow-up, 8.8 ± 3.6 months; range, 3-19 months). A study of 61 patients with seasonal allergic rhinitis taking nasal fluticasone for 1 year showed no increased risk for glaucoma.However, no information was described regarding their glaucoma risk status before steroid use in this study. Six cases of increased IOP associated with combined nasal and inhaled steroid use in non-glaucomatous patients have been reported.

Considering the large number of patients on nasal steroids; It is surprising that no one has investigated if nasal steroid use is contraindicated in glaucoma patients.
Chemically induced dimerizers (AbCIDs) have emerged as one of the most powerful tools to artificially regulate signaling pathways in cells; however, no facile method to identify or design these systems currently exists. The present invention provides a methodology to rapidly generate antibody-based chemically induced dimerizers (AbCIDs) from known small-molecule-protein complexes by selecting for synthetic antibodies that recognize the chemical epitope created by the bound small molecule. Success of this strategy is demonstrated by generating ten chemically- inducible antibodies against the BCL-xL/ ABT-737 complex. Three of the antibodies are highly selective for the BCL-xL/ ABT-737 complex over BCL-xL alone. Two exemplary important cellular applications of AbCIDs are demonstrated by applying them intracellularly to induce CRISPRa-mediated gene expression and extracellularly to regulate CAR T-cell activation with the small molecule, ABT-737. ABT-737 is not toxic at the concentrations used to activate AbCIDs in cells. AbCIDs provided by this invention are new and orthogonal AbCIDs, expanding the limited toolbox of available CIDs.